Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05397132 · ClinicalTrials.gov registry record
Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies
A clinical trial of Hematologic Malignancy, sponsored by Duke University.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT05397132 is a study of Hematologic Malignancy that is actively recruiting participants, run by Duke University. The registered enrollment target is 50 participants, below the 227-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05397132, a study of Hematologic Malignancy, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this IRB protocol is to perform immune profiling focusing on the measurement of Myeloid derived suppressor cells (MDSCs) over time in patients receiving Chimeric antigen receptor (CAR) T therapy and determine the correlation between immune profile and disease relapse/resistance in CAR T therapy.
Conditions Studied
Interventions
- GENETIC Blood draw
Study Locations (1)
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2026-11-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05397132
The ClinicalTrials.gov registry entry for NCT05397132 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 227-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (78% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematologic Malignancy appearing as the primary indexed condition, and to 1 intervention - of which Blood draw is the first listed.
NCT05397132 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05397132 about?
NCT05397132 is a clinical study titled "Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies". The primary purpose of this IRB protocol is to perform immune profiling focusing on the measurement of Myeloid derived suppressor cells (MDSCs) over time in patients receiving Chimeric antigen receptor (CAR) T therapy and determine the correlation between immune profile and disease relapse/resistanc...
What is the current status of trial NCT05397132?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2022-05-27. Estimated completion is 2026-11-01.
What conditions does trial NCT05397132 study?
This clinical trial studies the following conditions: Hematologic Malignancy.
What interventions are being tested in trial NCT05397132?
The interventions under investigation include: Blood draw (GENETIC).
Who is sponsoring clinical trial NCT05397132?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05397132 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis
RECRUITING
-
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
RECRUITING · Phase 3
-
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.